Insider Selling: Artivion (NYSE:AORT) CEO Sells 13,936 Shares of Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 13,936 shares of the company’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $35.69, for a total transaction of $497,375.84. Following the transaction, the chief executive officer owned 766,095 shares of the company’s stock, valued at approximately $27,341,930.55. This trade represents a 1.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Price Performance

Shares of Artivion stock traded up $0.31 during mid-day trading on Wednesday, reaching $35.66. 300,261 shares of the stock traded hands, compared to its average volume of 399,410. The company has a quick ratio of 2.62, a current ratio of 3.53 and a debt-to-equity ratio of 0.49. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The stock has a market capitalization of $1.71 billion, a PE ratio of 178.32 and a beta of 1.59. The business has a 50-day moving average of $42.51 and a 200 day moving average of $43.14.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. The company had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, analysts predict that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AORT. Verition Fund Management LLC boosted its stake in Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock worth $716,000 after buying an additional 274 shares during the period. Entropy Technologies LP boosted its position in shares of Artivion by 6.0% during the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after purchasing an additional 310 shares during the period. State of Alaska Department of Revenue raised its position in Artivion by 1.8% in the third quarter. State of Alaska Department of Revenue now owns 23,294 shares of the company’s stock valued at $985,000 after purchasing an additional 414 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Artivion by 6.2% during the third quarter. PNC Financial Services Group Inc. now owns 8,232 shares of the company’s stock worth $349,000 after buying an additional 477 shares during the period. Finally, Arizona State Retirement System raised its holdings in shares of Artivion by 4.6% in the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after buying an additional 494 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AORT. Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research report on Friday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Canaccord Genuity Group cut their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.